Radiation therapy, when given in conjunction with a newly formulated chemotherapy regimen, improves survival rates up to 12 months for patients with inoperable non-small cell lung cancer (NSCLC), according to a recent study.
Patients with advanced, EGFR-mutant non-small cell lung cancer (NSCLC) lived almost twice as long without disease progression after initial treatment with an EGFR inhibitor compared with standard of care tyrosine kinase inhibitor (TKI) therapy.
A recent comparison between commonly-used therapies for untreated, advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) demonstrated superior efficacy and lower toxicity for one therapy, published in the New England Journal of Medicine (online August 31, 2017; doi:10.1056/NEJMoa1704795).
Two of the most common chemotherapy regimens may be comparable in terms of efficacy when used in combination with radiotherapy for treatment of non-small cell lung cancer (NSCLC), according to a recent study published in JAMA Oncology.
Patients with early stage metastatic non-small cell lung cancer (NSCLC) whose tumors express high levels of PD-L1 have improved quality of life with pembrolizumab treatment versus standard of care platinum-containing chemotherapy, according to new research.
Patients with non-squamous non-small cell lung cancer (NSCLC) have improved progression-free survival (PFS) if they switch from docetaxel to paclitaxel and bevacizumab treatments, according to new research.